February 3, 2026, Madison, WI — Scarab Genomics, a biotechnology company specializing in the engineered Clean Genome^® E. coli platform for reliable microbial production, today announced an exclusive licensing partnership with Bionova Scientific, a leading contract development and manufacturing organization (CDMO) supporting advanced biologics programs. Under the agreement, Bionova has obtained exclusive rights to utilize one of Scarab’s proprietary Clean Genome^® strains for plasmid DNA (pDNA) production.

Scarab’s Clean Genome platform comprises a library of engineered E. coli strains designed to eliminate mobile genetic elements, minimize genomic instability, and reduce burdensome host functions-resulting in higher plasmid yields, improved lot-to-lot consistency, and streamlined downstream purification. The strain licensed to Bionova incorporates Scarab’s production-enhancing genetic modifications optimized specifically for pDNA manufacturing.

“We’re excited to formalize this partnership with Bionova,” said Venkat Balakrishnan, PhD, Director of Commercial Operations at Scarab Genomics. “Their commitment to supporting innovative therapeutics aligns well with Scarab’s mission to provide high-performance microbial platforms that accelerate development and manufacturing for next-generation biologics.”

The exclusive license enables Bionova to integrate the Clean Genome strain into its pDNA production workflows to support client programs across modalities, including mRNA, viral vectors, and emerging genetic medicine platforms.

“Reliable access to high-quality plasmid DNA is critical for many of the programs we support,” said Darren Head, President at Bionova Scientific. “Scarab’s Clean Genome technology strengthens our ability to deliver consistent, scalable, and regulatory-aligned pDNA manufacturing solutions to our customers.”